Evogene Interest Income vs Depreciation And Amortization Analysis
EVGN Stock | USD 1.62 0.05 2.99% |
Evogene financial indicator trend analysis is much more than just examining Evogene latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Evogene is a good investment. Please check the relationship between Evogene Interest Income and its Depreciation And Amortization accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evogene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Evogene Stock, please use our How to Invest in Evogene guide.
Interest Income vs Depreciation And Amortization
Interest Income vs Depreciation And Amortization Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Evogene Interest Income account and Depreciation And Amortization. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Evogene's Interest Income and Depreciation And Amortization is -0.29. Overlapping area represents the amount of variation of Interest Income that can explain the historical movement of Depreciation And Amortization in the same time period over historical financial statements of Evogene, assuming nothing else is changed. The correlation between historical values of Evogene's Interest Income and Depreciation And Amortization is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Interest Income of Evogene are associated (or correlated) with its Depreciation And Amortization. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Depreciation And Amortization has no effect on the direction of Interest Income i.e., Evogene's Interest Income and Depreciation And Amortization go up and down completely randomly.
Correlation Coefficient | -0.29 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Interest Income
Income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments.Depreciation And Amortization
The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.Most indicators from Evogene's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Evogene current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evogene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Evogene Stock, please use our How to Invest in Evogene guide.At this time, Evogene's Issuance Of Capital Stock is very stable compared to the past year. As of the 26th of November 2024, Sales General And Administrative To Revenue is likely to grow to 1.53, while Selling General Administrative is likely to drop about 5.2 M.
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 1.4M | 3.3M | 171K | 162.5K | Depreciation And Amortization | 2.2M | 2.6M | 2.6M | 2.8M |
Evogene fundamental ratios Correlations
Click cells to compare fundamentals
Evogene Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Evogene fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 71.4M | 71.9M | 76.3M | 56.1M | 51.1M | 65.0M | |
Common Stock Shares Outstanding | 25.8M | 2.8M | 4.0M | 4.1M | 4.6M | 4.3M | |
Other Current Liab | 3.4M | 8.0M | 4.3M | 3.6M | 3.6M | 2.8M | |
Total Current Liabilities | 5.7M | 9.7M | 6.9M | 5.6M | 6.9M | 5.6M | |
Total Stockholder Equity | 50.1M | 46.0M | 54.0M | 27.9M | 12.1M | 11.5M | |
Other Liab | 3.3M | 3.7M | 4.3M | 14.8M | 17.0M | 17.8M | |
Accounts Payable | 1.0M | 863K | 1.5M | 1.0M | 1.8M | 1.2M | |
Cash | 34.7M | 46.2M | 32.3M | 29.0M | 20.8M | 26.8M | |
Short Term Investments | 12.1M | 2M | 21.5M | 6.4M | 10.3M | 9.8M | |
Other Current Assets | 894K | 1.4M | 1.7M | 1.0M | (708K) | (672.6K) | |
Total Liab | 11.1M | 15.0M | 12.9M | 21.3M | 18.0M | 14.6M | |
Property Plant Equipment | 5.3M | 3.9M | 4.2M | 4.1M | 3.7M | 4.7M | |
Property Plant And Equipment Net | 5.3M | 3.9M | 4.2M | 4.1M | 3.4M | 4.5M | |
Current Deferred Revenue | 423K | 119K | 264K | 101K | 750K | 987.3K | |
Net Debt | (31.8M) | (43.8M) | (29.7M) | (17.1M) | (9.3M) | (9.7M) | |
Retained Earnings | (155.9M) | (179.3M) | (207.1M) | (233.7M) | (257.6M) | (244.7M) | |
Non Current Assets Total | 22.3M | 20.1M | 19.4M | 18.4M | 16.6M | 13.2M | |
Cash And Short Term Investments | 46.9M | 48.2M | 53.9M | 35.4M | 31.1M | 55.2M | |
Net Receivables | 2.2M | 2.2M | 1.2M | 803K | 2.4M | 1.5M | |
Liabilities And Stockholders Equity | 71.4M | 71.9M | 76.3M | 56.1M | 51.1M | 66.8M | |
Non Current Liabilities Total | 5.4M | 5.4M | 6.0M | 15.7M | 11.0M | 6.5M | |
Other Stockholder Equity | 205.9M | 225.1M | 260.5M | 261.4M | 269.4M | 225.1M | |
Property Plant And Equipment Gross | 5.3M | 3.9M | 4.2M | 4.1M | 26.0M | 27.3M | |
Total Current Assets | 49.0M | 51.8M | 56.9M | 37.8M | 34.5M | 57.2M | |
Accumulated Other Comprehensive Income | 205.9M | 225.1M | 260.5M | 261.4M | 269.4M | 282.8M | |
Short Term Debt | 895K | 777K | 974K | 1.8M | 853K | 1.7M | |
Net Tangible Assets | 33.1M | 29.9M | 38.8M | 13.8M | 12.4M | 11.8M | |
Inventory | (894K) | (1.4M) | 92K | 566K | 1.7M | 1.8M | |
Non Current Liabilities Other | 3.4M | 2.9M | 3.3M | 3.7M | 4.2M | 3.7M | |
Net Invested Capital | 50.1M | 46.0M | 54.0M | 38.0M | 22.4M | 37.7M | |
Net Working Capital | 43.3M | 42.1M | 50.0M | 32.1M | 27.5M | 35.8M |
Pair Trading with Evogene
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Evogene position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Evogene will appreciate offsetting losses from the drop in the long position's value.Moving together with Evogene Stock
0.82 | ME | 23Andme Holding | PairCorr |
0.89 | VALN | Valneva SE ADR | PairCorr |
0.77 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
Moving against Evogene Stock
0.63 | MDGL | Madrigal Pharmaceuticals | PairCorr |
0.5 | RNXT | RenovoRx | PairCorr |
0.45 | NXGLW | NexGel Warrant | PairCorr |
0.4 | KZR | Kezar Life Sciences | PairCorr |
0.35 | MLYS | Mineralys Therapeutics, | PairCorr |
The ability to find closely correlated positions to Evogene could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Evogene when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Evogene - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Evogene to buy it.
The correlation of Evogene is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Evogene moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Evogene moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Evogene can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evogene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Evogene Stock, please use our How to Invest in Evogene guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evogene. If investors know Evogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evogene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.46) | Revenue Per Share 1.881 | Quarterly Revenue Growth 0.398 | Return On Assets (0.28) | Return On Equity (0.82) |
The market value of Evogene is measured differently than its book value, which is the value of Evogene that is recorded on the company's balance sheet. Investors also form their own opinion of Evogene's value that differs from its market value or its book value, called intrinsic value, which is Evogene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evogene's market value can be influenced by many factors that don't directly affect Evogene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evogene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evogene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evogene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.